CAR T cells redirected to B7-H3 for pediatric solid tumors: Current status and future perspectives

Area of Science:

• Immunology
• Pediatric Oncology
• Cancer Therapy

Background:

• Pediatric patients with relapsed or refractory solid tumors have limited treatment options.
• B7-H3 (CD276) is a promising target due to its high expression in various pediatric solid tumors and limited normal tissue expression.

Purpose of the Study:

• To review B7-H3-targeted chimeric antigen receptor (CAR) T cell therapies for pediatric solid tumors.
• To outline preclinical development and active clinical trials.
• To identify and discuss strategies to overcome challenges in CAR T cell therapy for solid tumors.

Main Methods:

• Review of preclinical data on B7-H3-CAR T cell development.
• Analysis of the landscape of ongoing pediatric clinical trials.
• Identification of challenges and proposed solutions for CAR T cell therapy in solid tumors.

Main Results:

• B7-H3 is highly expressed across a spectrum of pediatric solid tumors, making it an attractive therapeutic target.
• Preclinical strategies and active clinical trials for B7-H3-CAR T cells are emerging.
• Key challenges include tumor infiltration, microenvironment resistance, and T cell persistence.

Conclusions:

• B7-H3-CAR T cell therapy represents a novel approach for pediatric solid tumors.
• Advanced CAR T cell designs and combination therapies are crucial for enhancing efficacy.
• Further research and clinical trials are needed to optimize this treatment modality.